<DOC>
	<DOCNO>NCT01195818</DOCNO>
	<brief_summary>The prevalence Sickle Cell Associated Nephropathy ( SCAN ) increase grow concern . Microalbuminuria detect early onset SCAN . Noteworthy , diabetic nephropathy , hyperfiltration seem frequent finding , , series , overall incidence 57 % suggest pathological link glomerular hyperpressure glomerulosclerosis occur several year . Nitric oxide ( NO ) deficiency renin angiotensin system ( RAS ) likely involved glomerular hyperpressure lead hyperfiltration . Renin angiotensin antagonist currently give NEPHROPROTECTION numerous nephropathy include SCAN despite available report . The percentage decrease albuminuria percentage responder ( ie patient normalize albuminuria ) never report knowledge SCAN patient time hyperfiltration . The focus study therefore 1 ) Quantify albuminuria reduction 6 month RAS treatment ( primary end point ) ; 2 ) Quantify glomerular filtration rate ( GFR ) reduction 6 month RAS treatment , test hypothesis beneficial effect RAS inhibitor several biomarkers assess hemolysis , NO inhibition endothelial damage ( secondary end point ) . The ultimate aim study identify relevant ( new ) biomarkers associate hyperfiltration and/or albuminuria decrease ( /normalization ) .</brief_summary>
	<brief_title>Albuminuria Reduction With Renin Angiotensin System Inhibitors SCA Patients</brief_title>
	<detailed_description>This non randomized prospective multicentered study test effect RAS treatment wash period end study . Enrollment inform consent perform three AP-HP center . Visit n° 1 performed Hospital Tenon Center ( FONCTIONNEL Exploration Service ) final eligibility follow several investigation aim measure albuminuria , basal GFR ( 51 cr EDTA clearance ) , cardiac parameter ( doppler study ) ; aortic stiffness ( aortic pulse wave velocity ) endothelial dysfunction ( microvascular laser-doppler , blood urine sample assessment several biomarkers ) . At end evaluation , Ramipril administration initiate ( least six month ) . Tolerance check visit n°2 ( month 1 ) ( clinical examination ) visit n°3 ( month 6 ) ( clinical examination ) . Patients contact investigator every two month visit order evaluate tolerance . In case cough Ramipril , treatment may change Irbesartan . Posology treatment may reduce case intolerance . Treatment full dose ( Ramipril 5mg/day Irbesartan ( 300mg/day ) obtain visit 2 stop end visit 3 : Assessment RAS treatment effect albuminuria , GFR , heart , aorta microvessels perform visit 3 ( RAS treatment ) procedure visit 1 . Visit 4 performed 1 month wash period order check whether expect reduction albuminuria RAS treatment sustain .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Homozygous sickle cell disease &gt; 18 year Patient social insurance Albuminuria/ urinary creatinin &gt; 10 mg/mmol creatinin ( 2 different time ) MDRD &gt; 140 ml/min/1.73m2 . Written inform consent Hemoglobin SC Sbetathalassemia disease Patient currently treat : lithium , aspirin , antihypertensive drug , non steroidantiinflammatory drug . Pregnancy Woman without contraception Transfusion within last 3 month Intolerance RAS inhibitor Treatment RAS last month Patient Congenital galactosemia malabsorption glucose lactase deficiency Treatment hydroxyurea begin change last 3 month Infection HIV C hepatitis Angioedema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Albuminuria , hyperfiltration , RAS inhibitor , ADMA</keyword>
</DOC>